Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin cancer. Now, researchers at UCLA’s Jonsson Comprehensive Cancer Center, working with investigators … Continue reading →